Gabriel Martínez-Botella

Statistics

Publications

Citations

933

H-Index

Active since

2007

Affiliations

Vertex Pharmaceuticals (United States)(Current)

AstraZeneca (United States)

Horizon Discovery (United Kingdom)

Sage Therapeutics (United States)

University of Maryland, Baltimore

Gabriel Martínez-Botella is an author at Vertex Pharmaceuticals (United States) specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

2007–2021

Publications

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Ursula A. Germann, Brinley F. Furey, William Markland et al. · Molecular Cancer Therapeutics · 2017 · 234 citations

Medicine, Oncology, Pharmacology +16

Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control

Alex M. Aronov, Qing Tang, Gabriel Martínez-Botella et al. · Journal of Medicinal Chemistry · 2009 · 145 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17

Flipped Out: Structure-Guided Design of Selective Pyrazolylpyrrole ERK Inhibitors

Alex M. Aronov, Christopher Baker, Guy W. Bemis et al. · Journal of Medicinal Chemistry · 2007 · 122 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock et al. · Journal of Medicinal Chemistry · 2015 · 89 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Antibacterial Inhibitors of Gram-Positive Thymidylate Kinase: Structure–Activity Relationships and Chiral Preference of a New Hydrophobic Binding Region

Sameer Kawatkar, Thomas A. Keating, N.B. Olivier et al. · Journal of Medicinal Chemistry · 2014 · 63 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

1–5 of 13